Retrovir Articles
FDA Panel Recommends Fomivirsen Be Approved
23 July 1998
First Data With USB's Lodenosine
9 July 1998
GW's Abacavir Combo As Potent As PI Regimen
30 June 1998
WHO Model List Of Essential Drugs
23 June 1998
New Drugs May Address HIV In Brain
15 June 1998
BioChem Begins Ph I BCH-10652 Trial
7 May 1998
Gilead's Preveon Sees Success In HIV And Hep B
8 April 1998
GW's Abacavir In Expanded-Access
19 March 1998
GW Cuts AIDS Drug Prices For Poorer Countries
13 March 1998
Glaxo Wellcome Profits Hit By Strength Of Sterling
19 February 1998
A Real Challenge To HIV With New Therapies?
12 February 1998
Danger Of "Too-Fast" Drug Approvals
11 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Promising Data With New GW Therapies
5 February 1998
P&U Suspends Rescriptor Trial
5 February 1998
DuPont Merck To File Sustiva NDA Soon
5 February 1998
B-MS' Stavudine "As Effective As" AZT
5 February 1998
B-MS' Zerit Overtakes Glaxo's Zidovudine
30 January 1998
Agouron's Viracept OKed In Europe
29 January 1998
US Biosciences Signs CRADA With NCI
22 January 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
Remune Interim Data Due In 2Q98
11 December 1997
HIVID Combination Gets EU Approval
4 December 1997
EU Approval Granted For Combivir
4 December 1997
UK Approves GW's Combivir
27 November 1997
Can AZT Cause Cancer?
6 November 1997
Can Protease Inhibitor Resistance Be Combatted?
4 November 1997
Ph II Data With Vertex' 141W94
20 October 1997
Roche's Invirase Confers Survival Benefit
20 October 1997
Zerit/3TC More Effective Than AZT/3TC
20 October 1997
Combo Therapy With DuPont Merck's Sustiva
20 October 1997
Norvir Success In Pediatric HIV
16 October 1997
Long-Term Efficacy With Agouron's Viracept
15 October 1997
NDA Filed For New Soft-Gel Saquinavir
9 October 1997
New Jersey Rx Form To Beat Fraud
1 October 1997
GW's Combivir Approved In The USA For HIV
1 October 1997
HIV Undetectable With Crixivan Cocktail
17 September 1997
B-MS' Zerit Granted EU Approval
22 August 1997
GW's Abacavir Enters Open Label Trial
22 August 1997
Underlying Growth Healthy At GW Despite Strong L
6 August 1997
Vertex And GW Begin Pediatric 141W94 Trial
17 July 1997
AIDS Activists Boycott Glaxo's Zantac
9 July 1997
AIDS Study Terminated In Children
3 July 1997
Roche Shows Three HIV Drugs Cut AIDS Onset
26 June 1997
HIV Drug-Resistant Strain Reported
9 June 1997
Investors Impressed With Glaxo Wellcome Pipeline
12 May 1997
Promising Long-Term Data With Agouron's Viracept
21 April 1997
First Approval For Delavirdine NNRTI
7 April 1997
New CPAC Approvals Include Two NCEs
7 April 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
Indinavir-Based Regimen Cuts Mortality In AIDS
3 March 1997
Vertex And Glaxo Wellcome Begin Ph III With AIDS Therapy
24 February 1997
Remune Plus Drugs For HIV
24 February 1997
Can HIV Be Eliminated?
3 February 1997
No Resistance With Vertex' HIV Therapy?
3 February 1997
Promise With Agouron's Viracept & Roche's Invirase
3 February 1997
BI's Viramune Safe In Pregnancy
3 February 1997
Triangle Reports Data On NNRTI For HIV
27 January 1997
Vertex HIV Protease Inhibitor In Phase II
20 January 1997
Spanish Health Care Spending On AIDS
13 January 1997
Zocor "Will Be World's Top-Selling Drug In 2005"
13 January 1997
Split Verdict From Panel On P&U's Delavirdine
2 December 1996
Cost-Effectiveness Of New HIV Therapy And The Lack Of Euro-Purchase
25 November 1996
ACIC Sells Manufacturing Division To Apotex
14 October 1996
New Data On Anti-HIV Drugs Presented
30 September 1996
First Launch Of Boehringer Ingelheim's Nevirapine
2 September 1996
USA Forms Coalition In The Rush To Fight AIDS
19 August 1996
High French Hospital Spending Hits Local Drugmakers
12 August 1996
Delavirdine Filed In USA; NNRTI Role Reviewed
29 July 1996
Ritonavir Triple Therapy
29 July 1996
Lamivudine Study Halted Early On Ethical Grounds
29 July 1996
How Feasible Is HIV Eradication?
22 July 1996
Nevirapine Triple Combo Shows Potent Activity
22 July 1996
GW's Nucleoside 1592U89 Shows Early Promise
22 July 1996
SciClone's Zadaxin For HIV
22 July 1996
No Euphoria Over AIDS Drugs Among Investors
22 July 1996
AIDS Meeting; Guarded Optimism Replaces Pessimism
15 July 1996
Glaxo Wellcome And Vertex Get HIV Patent License
8 July 1996
Boehringer's Viramune Receives US Approval
1 July 1996
Can HIV be Eradicated From An Infected Person?
1 July 1996
EMEA Approves Three More Products
3 June 1996
Lamivudine Counters HIV/HBV Co-Infection
20 May 1996
3TC Royalties Mean Profit For BioChem Pharma
13 May 1996
...And Backs Approval Of Glaxo Wellcome's Lamivudine
29 April 1996
-Hybridon's Injectable GEM 91
22 April 1996
Barr Mounts Challenge To US Patents For Prozac
22 April 1996
Merck's Crixivan Is Third Protease Inhibitor Cleared
25 March 1996
HemisphereRx' Ampligen
18 March 1996
Neupogen Approved In UK For Neutropenia In AIDS
18 March 1996
Norvir Launch Soon As FDA Clears 2nd Protease Inhibitor
11 March 1996
Zantac Sales Slide 4% At Glaxo Wellcome
11 March 1996
Antivirals "Now 9% Of Anti-Infectives Market"
11 March 1996
Moves In HIV Therapy As FDA Panel Delivers Verdicts
4 March 1996
Triple Therapies For HIV Provide Encouraging Data
5 February 1996
CPMP Backs Stavudine
29 January 1996
Triangle Pharmaceuticals / Misubishi Chemical : deal for MKC-422
29 January 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
